ArticleDiscover oncology2025
Systematic analysis identifies CDKN2A as a prognostic biomarker for hepatocellular carcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pan-cancer analysis of role of LOXL4 and experiment validation in osteosarcoma.Discover oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatocellular carcinoma (HCC) ranks as the fifth most prevalent malignancy worldwide. Disruptions in copper homeostasis adversely affect liver function. Cuproptosis, a recently defined form of regulated cell death triggered by intracellular copper accumulation, disrupts the tricarboxylic acid cycle and mitochondrial respiration. However, the specific roles and mechanisms of cuproptosis-related genes (CRGs) in HCC pathogenesis remain incompletely understood. MATERIALS AND
methodsWe systematically evaluated the expression of 10 CRGs in HCC tissues versus adjacent normal tissues. Bioinformatics analyses included Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment, and Gene Set Enrichment Analysis (GSEA) were performed. Immune infiltration levels within the tumor microenvironment were assessed. The prognostic significance of CDKN2A was evaluated using Kaplan-Meier (KM) survival analysis and univariate/multivariate Cox proportional hazards regression. CDKN2A protein expression was validated using immunohistochemistry (IHC).
resultsCDKN2A was significantly overexpressed in HCC compared to normal tissues. Bioinformatics analyses implicated CDKN2A in DNA replication, organelle fission, and cell cycle checkpoint signaling. Immune-related analysis revealed that high CDKN2A expression correlated positively with dendritic cell (DC) and Th2 cell infiltration, but negatively with CD8 + T cell and natural killer (NK) cell infiltration. KM analysis demonstrated that high CDKN2A expression predicted significantly shorter overall survival in HCC patients. Univariate and multivariate Cox regression identified CDKN2A as an independent prognostic risk factor.
conclusionsThis study demonstrates that CDKN2A is significantly overexpressed in HCC and plays a role in immune microenvironment modulation. CDKN2A serves as a promising independent prognostic biomarker for HCC, associated with poorer patient survival.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.